Sanofi to develop mRNA vaccines using ex-Shire platform

By Flora Southey contact

- Last updated on GMT

Getty/littlehenrabi
Getty/littlehenrabi
Sanofi Pasteur has teamed with Translate Bio to develop mRNA vaccines for infectious diseases, using a platform developed by subsidiaries of Shire plc.

Clinical-stage mRNA therapeutics firm Translate Bio has announced a three-year collaboration with Sanofi Pasteur – the vaccine unit of Sanofi – to develop up to five undisclosed infectious disease pathogens.

Messenger RNA (mRNA) medicine works by instructing ribosomes inside cells to produce a desired therapeutic protein when injected into a platform. mRNA vaccines are designed to deliver the nucleotide sequence, encoding any protein associated with prevention or treatment of a pathogen.

According to the agreement terms, Sanofi Pasteur will fund all research and development activities – conducted jointly with Translate Bio – and pay the biotech an upfront fee of $45m (€38m) and up to $805m in tiered royalty payments.

In return, Sanofi Pasteur will receive exclusive worldwide commercialisation rights for the developed vaccines.

The firms will develop the vaccines using the MRT platform, which Translate Bio – formerly RaNA Therapeutics – acquired from Shire plc in January last year​.

“We believe mRNA technology has significant potential for rapid and versatile manufacturing, reduced industrialisation costs for multiple vaccines, and the improved breadth of immune response for infectious disease vaccines,” ​said Sanofi Pasteur’s John Shiver in a statement​.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars